175 related articles for article (PubMed ID: 37989823)
21. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
22. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
23. Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas.
Wang K; Gui L; Lu H; He X; Li D; Liu C; Liu S; Wang X
Front Immunol; 2023; 14():1189752. PubMed ID: 37583698
[TBL] [Abstract][Full Text] [Related]
24. Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients.
Tang AL; O'Neil T; McDermott S; Tripathi S; Tikhtman R; Mark JR; Patil Y; Tabangin M; Altaye M; Wise-Draper TM; Zender CA
JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):935-939. PubMed ID: 36006622
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and Impact of HPV-Associated p16 Expression on Head and Neck Squamous Cell Carcinoma in Thai Patients.
Jiarpinitnun C; Larbcharoensub N; Pattaranutaporn P; Chureemas T; Juengsamarn J; Trachu N; Lukerak S; Chansriwong P; Ngamphaiboon N
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1679-1687. PubMed ID: 32592364
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.
Xu J; Yan C; Li Z; Cao Y; Duan H; Ke S
Ann Surg Oncol; 2023 Mar; 30(3):1597-1613. PubMed ID: 36380254
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck.
Weiss JM; Grilley-Olson JE; Deal AM; Zevallos JP; Chera BS; Paul J; Knowles MF; Usenko D; Weissler MC; Patel S; Hayes DN; Hackman T
Cancer; 2018 Jul; 124(14):2986-2992. PubMed ID: 29741773
[TBL] [Abstract][Full Text] [Related]
28. [Prediction of pathological remission of head and neck squamous cell carcinoma patients after neoadjuvant immunochemotherapy and construction of clinical model based on clinical features and inflammatory markers].
Lin QH; Yan SD; Zhang X; Chen SW; Li XY; Zhang Y; Zhang ST; Song M
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):357-365. PubMed ID: 38599643
[No Abstract] [Full Text] [Related]
29. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
[TBL] [Abstract][Full Text] [Related]
31. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Ferrarotto R; Amit M; Nagarajan P; Rubin ML; Yuan Y; Bell D; El-Naggar AK; Johnson JM; Morrison WH; Rosenthal DI; Glisson BS; Johnson FM; Lu C; Mott FE; Esmaeli B; Diaz EM; Gidley PW; Goepfert RP; Lewis CM; Weber RS; Wargo JA; Basu S; Duan F; Yadav SS; Sharma P; Allison JP; Myers JN; Gross ND
Clin Cancer Res; 2021 Aug; 27(16):4557-4565. PubMed ID: 34187851
[TBL] [Abstract][Full Text] [Related]
32. The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus.
Lin JW; Hsu CP; Yeh HL; Chuang CY; Lin CH
J Chin Med Assoc; 2018 Jan; 81(1):18-24. PubMed ID: 29066057
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
[TBL] [Abstract][Full Text] [Related]
34. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors.
Specenier P
Curr Opin Otolaryngol Head Neck Surg; 2021 Apr; 29(2):168-177. PubMed ID: 33605624
[TBL] [Abstract][Full Text] [Related]
36. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma.
Shi MW; Huang J; Sun Y
Curr Med Sci; 2023 Apr; 43(2):213-222. PubMed ID: 36971976
[TBL] [Abstract][Full Text] [Related]
38. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.
Redman JM; Friedman J; Robbins Y; Sievers C; Yang X; Lassoued W; Sinkoe A; Papanicolau-Sengos A; Lee CC; Marte JL; Turkbey E; Mydlarz W; Joshi A; London NR; Pierce M; Taylor R; Hong S; Nguyen A; Soon-Shiong P; Schlom J; Gulley JL; Allen CT
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35727629
[TBL] [Abstract][Full Text] [Related]
39. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Lv H; Huang C; Li J; Zhang F; Gai C; Liu Z; Xu S; Wang M; Li Z; Tian Z
Front Immunol; 2022; 13():1100750. PubMed ID: 36741358
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial).
Huang Y; Sun J; Li J; Zhu D; Dong M; Dou S; Tang Y; Shi W; Sun Q; Zhao T; Zhou Z; Zhou X; Liu Y; Li J; Zhu G; Zhang D; Chen Y; Zhu Q; Ju W; Zhong L
Int J Surg; 2023 Aug; 109(8):2220-2227. PubMed ID: 37288582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
